Skip to content

21-056 - Study of AVB-S6-500 in Combination With Paclitaxel vs Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Status: open

A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer

Treatment for Ovarian Cancer

Contact Us


To evaluate the effect of AVB-S6-500 plus Paclitaxel (PAC) (AVB-S6-500 + PAC) versus Placebo and PAC (Placebo + PAC) on progression-free survival (PFS) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) criteria, in subjects with platinum-resistant recurrent ovarian cancer.

Providers Associated With This Trial

Principle Investigator

    Sub Investigators

    This link will open in a new tab or window.